选刊解惑,VIP专家在线等!精彩提问获免费选刊!

2016-03-03 MedSci MedSci原创

如何从3000多种SCI期刊中,选择最适合作者SCI文章来发表,需要作者对SCI杂志认知度、熟悉度、投稿量等众多指标做出综合评定。如何选刊,选择哪种期刊来投稿,已经成为每位发表SCI文章作者的必修课。2016年3月,梅斯迎来选刊解惑周(3月3日至3月9日),为所有梅斯用户选刊相关问题提供免费咨询服务。对SCI选刊存在困惑的朋友,可以通过在MedSci医学App上“Sci期刊”里面期刊提问,就有机会


如何从3000多种SCI期刊中,选择最适合作者SCI文章来发表,需要作者对SCI杂志认知度、熟悉度、投稿量等众多指标做出综合评定。如何选刊,选择哪种期刊来投稿,已经成为每位发表SCI文章作者的必修课。

2016年3月,梅斯迎来选刊解惑周(3月3日至3月9日),为所有梅斯用户选刊相关问题提供免费咨询服务。对SCI选刊存在困惑的朋友,可以通过在MedSci医学App上“Sci期刊”里面期刊提问,就有机会获得MedSci选刊专家的回复。

过去八年,MedSci选刊专家为广大医生就科研成果发表选刊方面答疑解惑。“选刊解惑周”活动期间,提问者在MedSci医学App里面发问后,MedSci选刊专家将给予点评,当日可获得专家点评。我们每日将从问答中选出5个最佳问答,并赠送提问者价值2000元的选刊服务。梅斯医生特权日(周三,3月9日),我们将一次赠送10个2000元选刊服务。期待您的参与!

获取快速上手攻略:如何在MedSci医学App里面提出选刊的疑惑?

1)扫描二维码下载MedSci医学App,或直接点击此处下载(超链接:http://www.bioon.com/index_forword.asp?id=5969



2)进入SCI期刊,通过分类或直接搜索关键词,点击相应期刊。




3)可以在任何相关期刊下发布问题(对于没有相关期刊发表经验提问者,请直接忽视对应期刊的“投稿命中率”、“一审时间”)




版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-10-02 chendoc254
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-03-09 iwangyj

    中草药药理的文章投sci有什么注意的地方吗?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-03-09 临医人

    老师您好,能帮忙选刊和投稿吗,万谢!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-03-08 dongdng

    我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-03-08 dongdng

    我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1746682, encodeId=10af1e4668260, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Sun Oct 02 09:36:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68412, encodeId=77bc68412f4, content=中草药药理的文章投sci有什么注意的地方吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40f31698077, createdName=iwangyj, createdTime=Wed Mar 09 18:50:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68408, encodeId=a04a6840809, content=老师您好,能帮忙选刊和投稿吗,万谢!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9731697787, createdName=临医人, createdTime=Wed Mar 09 17:29:00 CST 2016, time=2016-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68146, encodeId=dc8468146f7, content=我的文章2015年7月份nerulogy india 一直pre_acceptance proof 状态,至今未有答复,请问怎么回事? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:49:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68143, encodeId=124e681436c, content=我的文章2015年7月份就一直在pre-accepance proof 状态,至今未有任何答复,请问是怎么回事呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83c1697610, createdName= dongdng, createdTime=Tue Mar 08 14:13:00 CST 2016, time=2016-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67030, encodeId=9b296e03037, content=福利又要来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Mar 03 14:48:00 CST 2016, time=2016-03-03, status=1, ipAttribution=)]
    2016-03-03 老段

    福利又要来了

    0